PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 79 filers reported holding PRELUDE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,282,616 | -31.3% | 10,123,824 | 0.0% | 0.18% | -31.8% |
| Q2 2023 | $45,557,208 | -21.1% | 10,123,824 | 0.0% | 0.26% | -15.9% |
| Q1 2023 | $57,705,797 | -5.6% | 10,123,824 | 0.0% | 0.31% | -14.4% |
| Q4 2022 | $61,147,897 | -8.6% | 10,123,824 | 0.0% | 0.37% | -16.2% |
| Q3 2022 | $66,918,000 | +26.6% | 10,123,824 | 0.0% | 0.44% | +46.0% |
| Q2 2022 | $52,846,000 | -24.3% | 10,123,824 | 0.0% | 0.30% | -25.2% |
| Q1 2022 | $69,854,000 | -44.6% | 10,123,824 | 0.0% | 0.40% | -34.6% |
| Q4 2021 | $126,042,000 | -60.2% | 10,123,824 | 0.0% | 0.61% | -55.9% |
| Q3 2021 | $316,370,000 | +9.2% | 10,123,824 | 0.0% | 1.39% | +9.1% |
| Q2 2021 | $289,845,000 | -33.9% | 10,123,824 | 0.0% | 1.27% | -33.1% |
| Q1 2021 | $438,665,000 | -39.4% | 10,123,824 | +0.1% | 1.90% | -30.3% |
| Q4 2020 | $723,988,000 | +137.5% | 10,118,636 | 0.0% | 2.73% | +124.0% |
| Q3 2020 | $304,875,000 | – | 10,118,636 | – | 1.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $124,994,000 | 1.61% |
| Baker Brothers Advisors | 10,123,824 | $126,042,000 | 0.61% |
| Pinz Capital Management, LP | 43,800 | $545,000 | 0.21% |
| HHLR ADVISORS, LTD. | 583,333 | $7,262,000 | 0.11% |
| Rock Springs Capital Management LP | 368,959 | $4,594,000 | 0.11% |
| Nan Fung Group Holdings Ltd | 20,350 | $253,000 | 0.08% |
| Virtus ETF Advisers LLC | 13,815 | $172,000 | 0.06% |
| PDT Partners, LLC | 35,907 | $447,000 | 0.03% |
| Jump Financial, LLC | 36,900 | $459,000 | 0.03% |
| Parkwood LLC | 12,667 | $158,000 | 0.03% |